Therapeutic potential of Parabacteroides distasonis in gastrointestinal and hepatic disease
MedComm · 2024-12 · 5 (12)
DOI: 10.1002/mco2.70017 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 16.12.2024. Verfasst von Jingyi Duan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology & Hepatology Laboratory of Hepato-intestinal Diseases and Metabolism Frontiers Science Center for Disease-Related Mole…. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 218 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, West China Hospital, Sichuan University, National Key Research and Development Program of China.
Abstract (Originalsprache)
Increasing evidences indicate that the gut microbiota is involved in the development and therapy of gastrointestinal and hepatic disease. Imbalance of gut microbiota occurs in the early stages of diseases, and maintaining the balance of the gut microbiota provides a new strategy for the treatment of diseases. It has been reported that Parabacteroides distasonis is associated with multiple diseases. As the next‐generation probiotics, several studies have demonstrated its positive regulation on the gastrointestinal and hepatic disease, including inflammatory bowel disease, colorectal cancer, hepatic fibrosis, and fatty liver. The function of P. distasonis and its metabolites mainly affect host immune system, intestinal barrier function, and metabolic networks. Manipulation of P. distasonis with natural components lead to the protective effect on enterohepatic disease. In this review, the metabolic pathways regulated by P. distasonis are summarized to illustrate its active metabolites and their impact on host metabolism, the role and action mechanism in gastrointestinal and hepatic disease are discussed. More importantly, the natural components can be used to manipulate P. distasonis as treatment strategies, and the challenges and perspectives of P. distasonis in clinical applications are discussed.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology & Hepatology Laboratory of Hepato-intestinal Diseases and Metabolism Frontiers Science Center for Disease-Related Molecular Network West China Hospital Sichuan University Chengdu China.
- Deparment of Pharmacy, Academician Workstation Jiangxi University of Chinese Medicine Nanchang China.
- Department of Gastroenterology & Hepatology, Huaxi Joint Centre for Gastrointestinal Cancer State Key Laboratory of Respiratory Health and Multimorbidity West China Hospital Sichuan University Chengdu China.
Förderung
- National Natural Science Foundation of China
- West China Hospital, Sichuan University
- National Key Research and Development Program of China
Zitieren
APA
Duan, J., Li, Q., Cheng, Y., Zhu, W., Liu, H., & Li, F. (2024). Therapeutic potential of Parabacteroides distasonis in gastrointestinal and hepatic disease. MedComm, 5(12). https://doi.org/10.1002/mco2.70017
Vancouver
Duan J, Li Q, Cheng Y, Zhu W, Liu H, Li F. Therapeutic potential of Parabacteroides distasonis in gastrointestinal and hepatic disease. MedComm. 2024;5(12). doi:10.1002/mco2.70017
BibTeX
@article{Duan2024,
author = {Duan, Jingyi and Li, Qinmei and Cheng, Yan and Zhu, Weifeng and Liu, Hongning and Li, Fei},
title = {Therapeutic potential of Parabacteroides distasonis in gastrointestinal and hepatic disease},
journal = {MedComm},
year = {2024},
volume = {5},
number = {12},
doi = {10.1002/mco2.70017}
}
EUVIMED